



### Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

### Kane Biotech to Webcast Live at Life Sciences Investor Forum on December 17

Dec 10 2020, 1:34 PM EST

### Kane Biotech Announces Launch of New Human Health OTC DermaKB™ Product Line

Dec 10 2020, 8:30 AM EST

### Kane Biotech Announces Third Quarter 2020 Financial Results

Nov 26 2020, 5:30 PM EST

### Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	15.21m
Last Price	\$0.14
52-Week	\$0.10 - \$0.26

01/14/2021 09:30 AM EST

### Investor Relations

Harbor Access LLC  
Graham Farrell  
Managing Partner  
130 King St. W  
Suite 1900  
Toronto, ON  
T: (416) 842 9003  
graham.farrell@harboraccessllc.com

### Board of Directors

#### Mr. Philip Renaud

Chairman

#### Mr. Mark Nawacki

Director

#### Marc Edwards

Director, Interim Chief Executive Officer

#### Rashieda Gluck

Director

### Kane Biotech Inc.

162-196 Innovation Drive  
Winnipeg, Manitoba R3T 2N2  
Canada

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.